Title

The Evaluation of Recombinant LH Supplementation in Patients With Suboptimal Response to Recombinant FSH Undergoing ICSI
In This Study, the Addition of rLH, Increasing the Dose of rFSH and the Control Groups Regarding the Results of IVF in These Patients.
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Study Participants

    137
The investigators aimed to evaluate patients who had In-vitro fertilization treatment and who had COH (controlled ovarian hyperstimulation) cycles applying long protocol with GnRH (gonadotropin-releasing hormone) analogue with suboptimal response to the rFSH. The investigators evaluated and compared the addition of rLH, increasing the dose of rFSH and the control groups regarding the results of IVF in these patients.
Aim

-We aimed to evaluate patients who had In-vitro fertilization treatment and who had COH (controlled ovarian hyperstimulation) cycles applying long protocol with GnRH (gonadotropin-releasing hormone) analogue with suboptimal response to the rFSH. We evaluated and compared the addition of rLH, increasing the dose of rFSH and the control groups regarding the results of IVF in these patients.

Material and Methods -Between 01.01.2009-30.04.2011, 137 patients presented with infertility to the unit of Assisted Reproduction Techniques- of the Department of Obstetrics and Gynecology- Meram Medical Faculty- Selcuk University and were planned for ICSI-ET (intracytoplasmic sperm injection-embryo transfer) with normal ovarian function, who had long protocol of GnRH analogue and COH (controlled ovarian hyperstimulation) with rFSH were included in the study. 52 patients were considered responsive to stimulation and composed the normal control group (Group 1). On the 7th day of stimulation transvaginal ultrasonography was carried out. Patients who had at least 6 follicles about 6-10mm but had no follicle above 10mm and E2 (Oestradiol) level of <250 pg / ml were considered to have suboptimal response to stimulation and were divided into two groups. For Group 2 (n = 50), 75IU / L rLH was added to the treatment, for Group 3 (n = 35), 75IU / L of rFSH was added to the treatment. IVF results were compared between the groups.
Study Started
Jan 31
2009
Primary Completion
Apr 30
2011
Study Completion
Apr 30
2011
Results Posted
Aug 19
2014
Estimate
Last Update
Mar 20
2015
Estimate

Drug fix dose r-FSH (Gonal-f)

recombinant follicle stimulation

  • Other names: puregon

Drug r-LH supplementation

recombinant luteinizing hormone

  • Other names: luveris

Drug r-FSH (Gonal-f)

recombinant follicle stimulation hormone

  • Other names: puregon

fix dose r-FSH (Gonal-f) Active Comparator

The patients who had normal ovarian response were included as the control group (Group 1). The dose of r-FSH (Gonal-f) was continued for the fix dose until the day of hCG in Group 1

r-LH supplementation to r-FSH Active Comparator

On day 7 of the stimulation, if at least six follicles between 6-10mm were present but there was no follicle over 10 mm on transvaginal ultrasound, E2 level was under 180 pg/ml, it has been considered that the patients had suboptimal response to the stimulation and were divided into Group 2. Group 2 received supplemental r-LH ( Lutropin alpha; Luveris, Merck Serono, France), 75IU/day to r-FSH (Gonal-f) treatment.

r-FSH (Gonal-f) Active Comparator

Group 3: Daily 75 IU/L r-FSH was added to r-FSH treatment until the end of ovarian stimulation.

Criteria

Inclusion Criteria:

Patients aged 23-39
Body mass index between 18 and 30 kg/m2
Baseline FSH ≤12 IU/l, E2 ≤ 80 pg/ml
The presence of both ovaries and uterine cavity capable of sustaining a pregnancy
Who had regular menstrual cycles (21-35 days) Confirmed absence of pregnancy and sufficient number of antral follicles on the transvaginal US examination on the 3rd day of menstruation
Who were having their first or second IVF trial.

Exclusion Criteria:

Grade III-IV endometriosis
Clinically significant condition preventing them from undergoing gonadotrophin treatment
More than two previous assisted cycles
Who had a single ovary
Unexplained gynaecological bleeding
Polycystic ovary or an ovarian cyst of unknown aetiology
Previously diagnosed with a space occupying lesion like submucous myoma , polyps, septum, synechia in the uterine cavity
Have a chromosomal anomaly.

Summary

Fix Dose r-FSH (Gonal-f)

r-LH Supplementation to r-FSH

r-FSH (Gonal-f)

All Events

Event Type Organ System Event Term

Pregnancy Rate

percentage of participants with a pregnancy (a b-HCG determination was obtained and considered positive if the value was greater than 10 mIU/ml)

Fix Dose r-FSH (Gonal-f) Group 1

64.7
percentage of pregnant participants

r-LH Supplementation to r-FSH Group 2

57.8
percentage of pregnant participants

r-FSH (Gonal-f) Group 3

32.4
percentage of pregnant participants

the Number of Oocytes Retrieved

median number of oocytes retrieved per participant

Fix Dose r-FSH (Gonal-f)

10.8
oocytes (Median)
Standard Deviation: 4

r-LH Supplementation to r-FSH

6.6
oocytes (Median)
Standard Deviation: 3.4

r-FSH (Gonal-f)

6.4
oocytes (Median)
Standard Deviation: 3.3

Number of Mature Oocyte

median number of mature oocytes retrieved per participant

r-LH Supplementation to r-FSH

5.5
oocytes (Median)
Standard Deviation: 2.8

r-FSH (Gonal-f)

5.5
oocytes (Median)
Standard Deviation: 3

Fix Dose r-FSH (Gonal-f)

8.9
oocytes (Median)
Standard Deviation: 3.3

Fertilization Rate

fertilization rate used to measure how many oocytes become fertilized by sperm cells

Fix Dose r-FSH (Gonal-f)

73.1
percentage of fertilized oocytes

r-LH Supplementation to r-FSH

74.9
percentage of fertilized oocytes

r-FSH (Gonal-f)

74.7
percentage of fertilized oocytes

Implantation Rates

Implantation rate is the percentage of embryos which successfully undergo implantation

Fix Dose r-FSH (Gonal-f)

34.8
percentage of embryo implantation

r-LH Supplementation to r-FSH

36.1
percentage of embryo implantation

r-FSH (Gonal-f)

15.0
percentage of embryo implantation

Total

137
Participants

Age, Continuous

29.5
years (Mean)
Standard Deviation: 4.7

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Fix Dose r-FSH (Gonal-f)

r-LH Supplementation to r-FSH

r-FSH (Gonal-f)